59% of Clinical Trial Sites Losing Eligible Patients to Process Inefficiencies, Survey Reveals
核心洞察
Nearly 6 in 10 clinical trial sites report that process inefficiencies are directly suppressing recruitment, reframing enrollment shortfalls as a throughput problem rather than a patient supply problem.
The WCG (搜索) 2024 Clinical Research Site Challenges Report found 39% of sites identified recruitment and retention as a top challenge, while 38% cited trial complexity as the number one issue.
Pre-screening coordination labor remains largely unfunded in sponsor-site contracts, creating an invisible workload that sites absorb until workflow slows and enrollment stalls.
Nearly six in ten clinical trial sites are losing eligible patients before they ever enroll — not because those patients do not exist, but because the operational machinery around identifying, contacting, and qualifying them is broken. A recent survey puts the figure at 59% of sites reporting that process inefficiencies are directly suppressing recruitment, a finding that reframes enrollment shortfalls as a throughput problem rather than a supply problem.
The instinct across the pharmaceutical industry has long been to treat recruitment shortfalls as a matter of thin patient populations or overly narrow protocols. The survey challenges that assumption, pointing instead to dysfunction baked into how most sites run their intake workflows.
Where the Workflow Breaks
The WCG (搜索) 2024 Clinical Research Site Challenges Report, which surveyed 852 clinical research sites globally, found that 39% of sites identified participant recruitment and retention as a top challenge. Study startup remained a consistent pressure point, cited by 35% of sites. Those two findings are connected: sites that struggle to activate cleanly almost always carry that instability forward into enrollment.
A delayed site initiation visit means the coordinator who trained on the protocol has rotated off. A budget amendment that took six weeks to execute means the screening log template was never finalized before the sponsor expected first-patient-in. Startup dysfunction does not resolve at activation — it metastasizes into recruitment paralysis.
The screening log often surfaces the problem fastest. At sites where recruitment is flagged as slow, the gap between the date of initial eligibility flag and the date of first patient contact attempt is frequently ten to fourteen days. That is not a patient availability problem; it is a coordinator bandwidth problem, a contact workflow problem, or a CTMS configuration problem — and none of those show up in a monitoring visit unless the CRA is specifically looking for them.
The Economics of Delay
The financial stakes are substantial. The Tufts Center for the Study of Drug Development (搜索) updated its day-of-delay analysis in 2023, finding that a single day of delay in drug development costs approximately $800,000 in unrealized prescription drug sales and $40,000 in direct daily clinical trial costs. Sites running recruitment workflows that add even two to three weeks of friction to the identification-to-screen timeline are compounding costs that most sponsors have never calculated at the site level.
Tufts CSDD research also established that drug developers routinely need to nearly double their original site count to hit enrollment targets — a patch that adds cost and calendar time without fixing the underlying dysfunction at any individual site. When 59% of those sites are already hemorrhaging patients to internal inefficiencies, adding more sites compounds the problem as much as it solves it.
The Unfunded Pre-Screening Burden
A counterintuitive dynamic sits at the center of this crisis: sponsors fund enrollment, but they rarely fund the workflow that produces enrollment. Study budgets routinely include line items for screening visits, lab processing, and per-patient completion fees. Almost none include a dedicated line for pre-screening coordination labor — the hours a clinical research coordinator spends reviewing charts against inclusion and exclusion criteria before a single patient is ever contacted. That work is invisible in the budget and constant in practice.
WCG (搜索)'s 2024 data flagged trial complexity as the number one challenge cited by sites, at 38%. Protocol complexity drives pre-screening labor up steeply: more criteria to cross-reference, more comorbidity exclusions to verify, more prior therapy wash-out windows to calculate. A site running a complex oncology protocol may spend forty-five minutes of coordinator time per potential patient just to determine the person is ineligible before contact. Multiply that across a pool of fifty flagged patients to find twelve screened, and the unpaid labor cost is substantial.
Technology's Promise and Its Limits
The U.S. AI-based clinical trial patient matching market was valued at $1.1 billion in 2024, and platforms promising to automate eligibility pre-screening against EHR data have proliferated. The promise is real — automated chart review against inclusion and exclusion criteria can cut pre-screening time meaningfully. However, the implementation reality at most community sites is that the platform requires EHR integration that the site's IT team has not prioritized, a data governance review that legal has not cleared, and a training workflow that the sponsor built for academic medical centers. The technology exists; the activation pathway often does not.
A 2024 report cited in Science Translational Medicine attributed a 47% increase in participant diversity and a 28% reduction in dropout rates to decentralized approaches across more than 500 trials. Those outcomes are real, but they depend on sites having the operational capacity to execute hybrid or remote workflows. A site choking on referral backlogs and manual pre-screening processes does not suddenly function better because a sponsor introduces an electronic consent tool. Technology layered onto a dysfunctional process produces a more expensive dysfunctional process.
Regulatory Recognition
The FDA recognized this structural issue when it finalized its guidance on enhancing clinical trial participation in December 2025, explicitly calling for trial designs and site practices that reflect real-world patient populations rather than the narrow cohorts that inefficient screening tends to produce. ICH E6(R3) Section 5.2 places responsibility on investigators to maintain adequate resources for trial conduct — and coordinator workflow capacity is a resource question, not just a staffing headcount question.
The Path Forward
For site operations teams, the most immediate lever is a pre-screening workflow audit before the next study opens. Map the steps between CTMS eligibility flag and first patient contact attempt, and put a target time on each one. If the site cannot get from flag to first contact within 48 hours, the bottleneck is a process problem that needs fixing before a sponsor SIV.
For sponsors and CROs, the ask is sharper: add a recruitment workflow assessment to every site qualification visit, separate from the standard regulatory binder and staff training checklist. Ask the coordinator to walk through what happens between patient identification and first contact. The answer tells more about a site's true enrollment capacity than any feasibility questionnaire.
The single metric worth tracking is screen failure rate broken out by site operational maturity, not protocol complexity. If sponsors and CROs start publishing that disaggregated data consistently, the industry will finally have a credible way to distinguish patient scarcity from site-level inefficiency — and to stop paying for more sites when the real investment belongs inside the ones already open. Watch for whether pre-screening labor starts appearing as a named deliverable in site contracts over the next 18 months; that will signal the industry has finally decided to pay for the work it has always required.